A Win for Science, with Profound Implications for Industry: FDA Rejects MDMA
Mad in America
AUGUST 14, 2024
That is surely a problem, but it’s also a documented problem for other drugs. The FDA usually bends over backwards to approve new drugs, particularly psychiatric drugs. Yet, in this instance, the advisory board complained about a lack of blinding and possible underreporting of harms. Why isn’t this concern raised about, say, antidepressants?
127 
Let's personalize your content